14 February 2024 in Science Translational Medicine
Adult lung resident stem/progenitor cells, including P63 + progenitor cells, have demonstrated the capacity for regeneration of lung epithelium in preclinical models. Here, we report a clinical trial of intrapulmonary P63 + progenitor cell transplantation in 28 participants with stage II to IV chronic obstructive pulmonary disease (COPD). Autologous P63 + progenitor cells were isolated from the airway basal layer of participants in the intervention group via bronchoscopic brushing, cultured for 3 to 5 weeks, and then transplanted back into the lungs via bronchoscopy at 0.7 × 10 6 to 5.2 × 10 6 cells per kilogram of body weight. Twenty patients were evaluable at the end of the study (intervention group, n = 17; control group, n = 3). No grade 3 to 5 adverse events (AEs) or serious AEs occurred. Although bronchoscopy-associated AEs were recorded in participants in the intervention group, other AEs were not substantial different between groups. Twenty-four weeks after transplantation, participants in the intervention group displayed improvement in gas transfer capacity [diffusing capacity of the lung for carbon monoxide (DLCO) change from baseline: +18.2%], whereas the control group experienced a decrease (DLCO change from baseline: −17.4%; P = 0.008). Furthermore, participants in the intervention group showed >30-meter increase in walking distance within 6 minutes. Transcriptomic analysis of progenitor cells isolated from responding and nonresponding individuals in the intervention group showed that higher expression of P63 was associated with treatment efficacy. In conclusion, transplantation of cultured P63 + lung progenitor cells was safe and might represent a potential therapeutic strategy for COPD.
28 August 2024 in Respirology
Background and Objective: Radiofrequency ablation (RFA) is an emerging treatment of lung cancer, yet it is accompanied by certain safety concerns and operational limitations. This first multi‐centre, large‐scale clinical trial aimed to investigate the technical performance, efficacy and safety of an innovative transbronchial RFA system for lung tumours. Methods: The study enrolled patients with malignant lung tumours who underwent transbronchial RFA using an automatic saline microperfusion system between January 2021 and December 2021 across 16 medical centres. The primary endpoint was the complete ablation rate. The performance and safety of the technique, along with the 1‐year survival rates, were evaluated. Results: This study included 126 patients (age range: 23–85 years) with 130 lung tumours (mean size: 18.77 × 14.15 mm) who had undergone 153 transbronchial RFA sessions, with a technique success rate of 99.35% and an average ablation zone size of 32.47 mm. At the 12‐month follow‐up, the complete ablation rate and intrapulmonary progression‐free survival rates were 90.48% and 88.89%, respectively. The results of patients with ground‐glass nodules (GGNs) were superior to those of the patients with solid nodules (12‐month complete ablation rates: solid vs. pure GGN vs. mixed GGN: 82.14% vs. 100% vs. 96.08%, p = 0.007). No device defects were reported. Complications such as pneumothorax, haemoptysis, pleural effusion, pulmonary infection and pleural pain were observed in 3.97%, 6.35%, 8.73%, 11.11% and 10.32% of patients, respectively. Two subjects died during the follow‐up period. Conclusion: Transbronchial RFA utilizing an automatic saline microperfusion system is a viable, safe and efficacious approach for the treatment for lung tumours, particularly for patients with GGNs. image
7 October 2023 in Stem Cells Translational Medicine
Background: Airway epithelium defects are a hallmark of recurrent benign tracheal stenosis (RBTS). Reconstructing an intact airway epithelium is of great importance in airway homeostasis and epithelial wound healing and has great potential for treating tracheal stenosis. Methods: An experimental study was conducted in canines to explore the therapeutic effect of autologous basal cell transplantation in restoring airway homeostasis. First, airway mucosae from human patients with recurrent tracheal stenosis were analyzed by single-cell RNA sequencing. Canines were then randomly divided into tracheal stenosis, Stent, Stent + Cells, and Stent + Cells + Biogel groups. Autologous airway basal cells of canines in the Stent + Cells and Stent + Cells + Biogel groups were transplanted onto the stenotic airway after modeling. A biogel was coated on the airway prior to basal cell transplantation in the Stent + Cells + Biogel group. After bronchoscopic treatments, canines were followed up for 16 weeks. Results: Single-cell RNA sequencing demonstrated packed airway basal cells and an absence of normal airway epithelial cells in patients with RBTS. Autologous airway basal cell transplantation, together with biogel coating, was successfully performed in the canine model. Follow-up observation indicated that survival time in the Stent + Cells + Biogel group was significantly prolonged, with a higher (100%) survival rate compared with the other groups. In terms of pathological and bronchoscopic findings, canines that received autologous basal cell transplantation showed a reduction in granulation hyperplasia as well as airway re-epithelialization with functionally mature epithelial cells. Conclusions: Autologous airway basal cell transplantation might serve as a novel regenerative therapy for airway re-epithelialization and inhibit recurrent granulation hyperplasia in benign tracheal stenosis.
12 August 2025 in Journal of Advanced Research
Benign tracheal stenosis (BTS) is characterized by granulation tissue hyperplasia, driven by abnormal fibroblast activation and excessive extracellular matrix deposition. Targeting these mechanisms with novel therapies may offer a promising approach to addressing or preventing re-stenosis. Our previous study demonstrated that airway basal stem cell (BSC) transplantation can inhibit granulation hyperplasia in BTS. Given the therapeutic potential of extracellular vesicles (EVs) as mediators in cell-based therapies, we investigated the in vivo efficacy of airway BSC-derived EVs (BSC-EVs) and explored their underlying mechanisms. BTS was induced in rabbits via tracheal mucosal injury. BSC-EVs were isolated, characterized, and intratracheally delivered. Then, therapeutic effects were evaluated using bronchoscopy, 18F-FAPI PET/CT, histology, and RNA-seq. The underlying mechanisms were investigated in vitro focusing on miRNA regulation of human airway fibroblasts (AFs). Our findings revealed that BSC-EVs significantly reduce granulation hyperplasia, promote ECM remodeling and improve collagen fiber alignment, leading to enhanced airway patency and prolonged survival. Mechanistically, we identified miR-30a-5p as a key functional cargo within BSC-EVs, which directly targets the fibroblast activation protein (FAP) gene. In vitro experiments demonstrated that miR-30a-5p mediates the anti-fibrotic effects of BSC-EVs by attenuating fibroblast activation, collagen contraction, and ECM deposition. These findings suggest that BSC-EVs represent a promising therapeutic strategy for BTS by inhibiting fibroblast activation and promoting ECM remodeling via the miR-30a-5p/FAP axis, offering a novel advancement beyond current treatment approaches.